6th January 2009
Proteome Sciences plc has entered inot a non-exclusive licencing agreement with Onicmmune Limited in lung cancer for the use of its Annexin 1 and Annexin 2 autoantibody patents for the fields of diagnosis and for monitoring treatment.
It is anticipated that a panel test will be launched in the first half of 2009.
For copy of Press Release License Agreement in Lung Cancer and Trading Update click here |